Topical tacrolimus for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis
Cornea Aug 15, 2017
Prado SB, et al. – A retrospective study is carried out to find out the effectiveness and safety of topical tacrolimus compounded in the Pharmacy Service for the treatment of subepithelial corneal infiltrates (SEIs) secondary to adenoviral keratoconjunctivitis. Topical tacrolimus, compounded in the pharmacy, appears to be a successful and safe option for the treatment of SEIs secondary to adenovirus keratoconjunctivitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
